ArQule

ARQL NASDAQ
10.35
+0.67
+6.92%
盘后: 10.49 +0.14 +1.35% 17:25 06/20 EDT
开盘
9.71
昨收
9.68
最高
10.39
最低
9.71
成交量
626.19万
成交均量(3M)
261.62万
52周最高
10.39
52周最低
2.230
换手率
5.73%
市值
11.31亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供ArQule ARQL股票价格,ArQule股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.
展开 >

最近浏览

名称
价格
涨跌幅